Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 4,108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Experimental 2 Clear all
Completed Not applicable Interventional Results available

Comparison of the Functional Walking Outcomes of Two Settings of a Commercially Available AFO in Adult Stroke Patients

NCT02122783
View directory record Official record
Conditions
Walking Aided by a Leg Brace in Stroke Subjects
Interventions
ADR™ brace resistance, Conventional brace resistance (using hard stops)
Device
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
21 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 31, 2026, 2:56 AM EDT
Suspended Phase 1 Interventional

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122
View directory record Official record
Conditions
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions
Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 31, 2026, 2:56 AM EDT
Completed No phase listed Observational

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

NCT02978586
View directory record Official record
Conditions
Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions
[Ga-68]PSMA PET/MR
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

NCT00500331
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, pioglitazone, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Mesa, Arizona • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

NCT04700072
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Pembrolizumab/Quavonlimab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 31, 2026, 2:56 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Paracetamol With Caffeine to Treat Episodic Tension Type Headache

NCT01755702
View directory record Official record
Conditions
Headache, Tension-Type
Interventions
Placebo, Experimental paracetamol + caffeine formulation, ibuprofen marketed formulation, Paracetamol marketed formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Pembroke Pines, Florida • Springfield, Massachusetts • Wellesley Hills, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Relapse Prevention for Smoking Cessation With Repetitive Transcranial Magnetic Stimulation

NCT02822703
View directory record Official record
Conditions
Smoking Cessation
Interventions
rTMS Active 20Hz, rTMS Sham
Device
Lead sponsor
The City College of New York
Other
Eligibility
21 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Not applicable Interventional

Creating Live Interactions to Mitigate Barriers

NCT03317769
View directory record Official record
Conditions
Schizophrenia
Interventions
Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Optimized social skills training, Unstructured support group sessions
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions

NCT01188031
View directory record Official record
Conditions
Healthy
Interventions
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2010 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT03349437
View directory record Official record
Conditions
COPD, Dyspnea
Interventions
Vitabreath Device, Pursed Lip Breathing
Device · Other
Lead sponsor
Philips Respironics
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Youngstown, Ohio • Jefferson Hills, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 31, 2026, 2:56 AM EDT
Recruiting Not applicable Interventional

Decentralized Clinical Trial of Effectiveness of EnergyPoints App in Cancer Survivors

NCT06754722
View directory record Official record
Conditions
Cancer-related Problem/Condition, Fatigue in Cancer Survivors, Sleep Disturbances, Health-related Quality of Life
Interventions
App to guide self-acupressure
Other
Lead sponsor
5 Point App, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

NCT02122913
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Larotrectinib (Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Aurora, Colorado • Boston, Massachusetts • Cleveland, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

NCT03956680
View directory record Official record
Conditions
Advanced Solid Cancers
Interventions
BMS-986301, Nivolumab, Ipilimumab
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations

NCT00481546
View directory record Official record
Conditions
Amaurosis of Leber, Retinal Diseases
Interventions
rAAV2-CBSB-hRPE65
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
8 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Phase 4 Interventional

Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil

NCT01965925
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Helping Invested Families Improve Veterans Experiences Study

NCT01777490
View directory record Official record
Conditions
Caregiver, Disabled Veterans, Referred to Long-term Care, Residing at Home, Hospice Ineligible
Interventions
Helping Invested Families Improve Veterans Experiences - Control, Helping Invested Families Improve Veterans Experiences - HI FIVES
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 31, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Social Cognition Training in Schizophrenia

NCT00587561
View directory record Official record
Conditions
Schizophrenia
Interventions
Social Cognition Interaction Training, WLC
Behavioral
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

NCT00847613
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 31, 2026, 2:56 AM EDT
Not listed Phase 2 Interventional

Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

NCT04263623
View directory record Official record
Conditions
Hyperhidrosis, Palmar Hyperhidrosis
Interventions
Dexmecamylamine HCl, Placebo
Drug · Other
Lead sponsor
Atacama Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 31, 2026, 2:56 AM EDT
Recruiting Not applicable Interventional

Cannabis and Processing Emotions Study

NCT06907979
View directory record Official record
Conditions
Cannabis Use Disorder, Severe
Interventions
TMS - Sham, TMS - Active iTBS, TMS - Active cTBS
Device
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04886596
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Placebo, RSVPreF3 OA vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
26,675 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Clinical Performance of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses

NCT06377488
View directory record Official record
Conditions
Visual Acuity
Interventions
JJVC Investigational Multifocal Toric Contact Lens manufactured in Senofilcon A (C3) material with UV blocker / HEV filter
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
15
States / cities
Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 31, 2026, 2:56 AM EDT
Completed Not applicable Interventional

Intellectual Impairment in Women With Breast Cancer

NCT00896324
View directory record Official record
Conditions
Breast Cancer
Interventions
Cognitive Rehabilitation, Active Neurofeedback Training, Neurofeedback Training (placebo / Sham)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 31, 2026, 2:56 AM EDT